Novartis's ARNI heart failure drug shines in PhIII
This article was originally published in Scrip
A major Phase III trial of Novartis's first-in-class candidate for chronic heart failure, LCZ696, is to close early because the evidence of its efficacy is so clear. Shares in the Swiss firm rose by 3.17% on the news on the morning of 31 March to CHF74.75 as experts suggested that the standard of care for heart failure might be about to change.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.